Literature DB >> 27737952

Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.

Irini Sereti1, Shelly J Krebs2,3, Nittaya Phanuphak4, James L Fletcher4, Bonnie Slike2,3, Suteeraporn Pinyakorn2,3, Robert J O'Connell2,3,5, Adam Rupert6, Nicolas Chomont7, Victor Valcour8, Jerome H Kim2,3, Merlin L Robb2,3, Nelson L Michael2,3, Daniel C Douek9, Jintanat Ananworanich2,3,4, Netanya S Utay10.   

Abstract

BACKGROUND: Serious non-AIDS events cause substantial disease and death despite human immunodeficiency virus (HIV) suppression with antiretroviral therapy (ART). Biomarkers of inflammation, coagulation cascade activation, and fibrosis predict these end-organ events. We aimed to determine whether ART initiation during acute HIV infection would attenuate changes in these biomarker levels.
METHODS: Plasma samples were obtained from participants starting ART during acute or chronic HIV infection and from HIV-uninfected participants from Bangkok, Thailand. Biomarkers of inflammation (C-reactive protein [CRP], interleukin 6, soluble interleukin 6 receptor [sIL-6R], soluble gp130, tumor necrosis factor [TNF]), enterocyte turnover (intestinal fatty acid binding protein [I-FABP]), lipopolysaccharide-induced monocyte activation (soluble CD14 [sCD14]), coagulation cascade activation [D-dimer], and fibrosis (hyaluronic acid [HA]) were measured at baseline and through 96 weeks of ART.
RESULTS: CRP, TNF, sIL-6R, I-FABP, sCD14, D-dimer, and HA levels were elevated in acute HIV infection. Early ART was associated with increased I-FABP levels but normalization of TNF, sIL-6R, and D-dimer levels. CRP, sCD14, and HA levels decreased during ART but remained elevated compared with HIV-uninfected participants. Higher sCD14, CRP, and D-dimer levels were associated with higher peripheral blood mononuclear cell and gut integrated HIV DNA levels. Decreases in sCD14 and CRP levels were correlated with increases in CD4 T-cell counts.
CONCLUSIONS: ART initiated in early acute HIV infection was associated with normalization of the coagulation cascade and several systemic inflammatory biomarkers, but the acute-phase response, enterocyte turnover, monocyte activation, and fibrosis biomarkers remained elevated. Additional interventions to attenuate inflammation may be needed to optimize clinical outcomes in persons with HIV infection. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  acute HIV infection; antiretroviral therapy; inflammation; monocyte activation; sIL-6R

Mesh:

Substances:

Year:  2016        PMID: 27737952      PMCID: PMC5215214          DOI: 10.1093/cid/ciw683

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  33 in total

1.  Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction.

Authors:  Ilais Moreno Velásquez; Zahra Golabkesh; Henrik Källberg; Karin Leander; Ulf de Faire; Bruna Gigante
Journal:  Atherosclerosis       Date:  2015-04-14       Impact factor: 5.162

2.  Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.

Authors:  Corrilynn O Hileman; Bruce Kinley; Valeska Scharen-Guivel; Kathy Melbourne; Javier Szwarcberg; Janet Robinson; Michael M Lederman; Grace A Mccomsey
Journal:  J Infect Dis       Date:  2015-01-12       Impact factor: 5.226

Review 3.  The end of AIDS: HIV infection as a chronic disease.

Authors:  Steven G Deeks; Sharon R Lewin; Diane V Havlir
Journal:  Lancet       Date:  2013-10-23       Impact factor: 79.321

4.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

5.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

6.  Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Authors:  Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections.

Authors:  Jacob D Estes; Levelle D Harris; Nichole R Klatt; Brian Tabb; Stefania Pittaluga; Mirko Paiardini; G Robin Barclay; Jeremy Smedley; Rhonda Pung; Kenneth M Oliveira; Vanessa M Hirsch; Guido Silvestri; Daniel C Douek; Christopher J Miller; Ashley T Haase; Jeffrey Lifson; Jason M Brenchley
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

8.  Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

Authors:  Punnee Pitisuttithum; Sorachai Nitayaphan; Prasert Thongcharoen; Chirasak Khamboonruang; Jerome Kim; Mark de Souza; Thippawan Chuenchitra; Robin P Garner; Darawan Thapinta; Victoria Polonis; Silvia Ratto-Kim; Penprapa Chanbancherd; Joseph Chiu; Deborah L Birx; Anne-Marie Duliege; John G McNeil; Arthur E Brown
Journal:  J Infect Dis       Date:  2003-07-03       Impact factor: 5.226

Review 9.  Can early therapy reduce inflammation?

Authors:  Netanya G Sandler; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2014-01       Impact factor: 4.283

10.  Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.

Authors:  Elizabeth Hamlyn; Sarah Fidler; Wolfgang Stöhr; David A Cooper; Giuseppe Tambussi; Mauro Schechter; Jose M Miro; Myra Mcclure; Jonathan Weber; Abdel Babiker; Kholoud Porter
Journal:  AIDS       Date:  2014-03-27       Impact factor: 4.177

View more
  90 in total

1.  Brief Report: Racial Comparison of D-Dimer Levels in US Male Military Personnel Before and After HIV Infection and Viral Suppression.

Authors:  Thomas A OʼBryan; Brian K Agan; Russell P Tracy; Matthew S Freiberg; Jason F Okulicz; Kaku So-Armah; Anuradha Ganesan; David Rimland; Tahaniyat Lalani; Robert G Deiss; Edmund C Tramont
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-15       Impact factor: 3.731

2.  Undetectable = Untransmittable and Your Health: The Personal Benefits of Early and Continuous Therapy for HIV Infection.

Authors:  Mark J Siedner; Virginia Triant
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

Review 3.  The microbiome and HIV persistence: implications for viral remission and cure.

Authors:  Wei Li A Koay; Lilly V Siems; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2018-01       Impact factor: 4.283

4.  Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.

Authors:  Charles S Venuto; Jihoon Lim; Susan Messing; Peter W Hunt; Grace A McComsey; Gene D Morse
Journal:  Antivir Ther       Date:  2018

Review 5.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

6.  Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.

Authors:  Vanessa El Kamari; Carlee Moser; Corrilynn O Hileman; Judith S Currier; Todd T Brown; Liz Johnston; Peter W Hunt; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

Review 7.  Probing the Interface of HIV and Inflammaging.

Authors:  Scott F Sieg; Carey L Shive; Soumya Panigrahi; Michael L Freeman
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-11       Impact factor: 5.071

8.  Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The Sabes Randomized Clinical Study.

Authors:  Javier R Lama; Rachel A Bender Ignacio; Ricardo Alfaro; Jessica Rios; Jorge Gallardo Cartagena; Rogelio Valdez; Carolyn Bain; Karin Sosa Barbarán; Manuel V Villaran; Christopher D Pilcher; Pedro Gonzales; Jorge Sanchez; Ann Duerr
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

Review 9.  Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations.

Authors:  Mabel Toribio; Tomas G Neilan; Markella V Zanni
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.071

10.  MicroRNAs: novel tools to block gut inflammation in HIV?

Authors:  Nichole R Klatt; Peter W Hunt
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.